Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction

Official title

Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction : a Randomized Open-label Non-inferiority Trial

Overview

Acute adhesive Small Bowel Obstruction (ASBO) is a public health issue: this is the 3rd cause of hospitalization in Digestive Surgery Departments, 20-30% of patients will be operated, the mortality rate per episode is 3%, the duration of hospitalization is 8 days (up to 16 if resection), and it is associated with a tremendous health care expenses. The working group on ASBO of the World Society of Emergency Surgery suggested two distinct approaches for the management of acute ASBO: non-operative management (NOM) which concerning around 85% of patients and operative management (OM) : * OM: if there is clinical signs of strangulation, peritonitis, bowel ischemia, or if IV CT Scan shows sign of ischemia, strangulation, peritonitis, or if the occlusion persists for more than 72 hours; * NOM in all other cases, including nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h. NGT is an old concept first describe for treatment of ASBO based on several studies made on the dog where he proved efficacy of NGT by aspirating gas in the stomach favorising venous decompression and survival of patients. Since, NGT became one of the pillars of NOM. However NGT is quite bad tolerated by patients (ranked the most painful hospital procedure), some of them refuse it, others put off after the beginning of the treatment and one of the most frequent complications of NGT is pneumonia, which is quite surprising when the first argument for its insertion is to avoid inhalation pneumonia. Four specific retrospectives studies showed that absence of NGT is possible in 20 to 80% of included patients and was associated with a decrease: in transit recovery time; in complications rate (including rates of pneumonia); in length of stay (LOS); without an increased risk of surgery or resection. 20-87% (a total of 922 patients) were managed successfully conservatively without NGT with a reduction LOS of 2-6 days compared with NGT. But none of this series focused on the patient relief as an endpoint. A retrospective critical analysis of our own management (January - December 2019, n=96) found that: only 17% of patients had a NGT during the IV CTscan, the presence of the NGT did not influence neither gastric volume nor the rate of full stomach, and gastric volume did not influence patient management. To summarize, the investigators therefore know that the insertion of a NGT is painful, does not relieve all patients, and has an unquantified therapeutic effect on the evolution of ASBO. That is why it is pertinent, in 2023, to question the useless of NGT in the treatment of ASBO, in selected patients. This study would be the first randomized controlled trial to focus on the absence of NGT for the NOM of patients with ASBO. The results of this study could lead to a change in the surgical practice. The absence of NGT in ASBO management appears to be an innovative practice, in rupture with the current practice. This is a part of the simplification of patients'care suffering from ASBO.

Interventions

• Procedure nasogastric tube
  nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.
• Other NOM without NGT insertion
  intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h

Primary outcome measures

• Decrease of complication rate in patient without NGT group compared to control group [Time frame: 3 years]

Secondary outcome measures (1)

• aspiration pneumonia rate in both patient groups [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

• Presence of an obstruction believed to be secondary to adhesions (abdominal pain and distention, nausea and/or vomiting, no gas and/or stool).
• Uncomplicated presentation (no signs of strangulation or peritonitis).
• IV CT scan of the abdomen consistent with an uncomplicated ASBO, (performed with a pillow to raise slightly the patient.
• Aged 18 or older.
• Provision of written, informed consent.
• Patient covered by French national health insurance.

Exclusion criteria

• An incarcerated and/or strangulated incisional hernia, colonic obstruction.
• No previous abdominal operation.
• Obstruction within 4 weeks after a recent operation.
• Gastrointestinal neoplasm in progress.
• Inflammatory bowel disease in progress.
• Abdominal radiotherapy in the last 6 months.
• Contraindication to intravenous contrast enhancement for the CT scan, pre-existing risks factors for pneumonitis.
• Antecedent of aspiration pneumonia.
• Age > 85 years.
• Orientation disturbance.
• Bedridden.
• Chronic cerebrovascular disease (cerebral infarction sequelae, Parkinson disease etc).
• Dementia.
• Gastroesophageal disorder (gastroesophageal reflux)
• Pregnancy or breastfeeding.
• Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision).
• Patients unable to provide informed consent.
• Age <18 years.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Other

Study locations

France · 1 center

• Amiens Universitary Hospital — Amiens

Identifiers

NCT: NCT06347120 · PI2024_843_0011

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗